QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-estrella-immunopharma-maintains-16-price-target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.

 estrella-immunopharma-announces-activation-of-second-clinical-site-for-ongoing-starlight-1-phase-iii-clinical-trial-evaluating-eb103-in-relapsed-or-refractory-b-cell-nhl-patients

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical com...

 d-boral-capital-maintains-buy-on-estrella-immunopharma-maintains-16-price-target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.

 estrella-immunopharma-announces-335m-private-placement-equity-financing-of-2333334-shares-of-its-common-stock-at-a-price-of-150share

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical com...

 d-boral-capital-maintains-buy-on-estrella-immunopharma-maintains-16-price-target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.

 estrella-immunopharma-announces-first-patient-dosed-in-second-cohort-of-dose-escalation-study-of-phase-iii-starlight-1-trial-for-eb103-to-treat-patients-with-advanced-b-cell-nhl

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical com...

 d-boral-capital-maintains-buy-on-estrella-immunopharma-maintains-16-price-target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.

 d-boral-capital-initiates-coverage-on-estrella-immunopharma-with-buy-rating-announces-price-target-of-16

D. Boral Capital analyst Jason Kolbert initiates coverage on Estrella Immunopharma (NASDAQ:ESLA) with a Buy rating and annou...

 estrella-immunopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION